Should You Buy DexCom Stock After Its Post-Earnings Sell-Off?
When a stock falls over a cliff after earnings, it can put investors into an unnerving situation: Should you average down, or simply get out of the stock entirely? It's not always an easy question to answer, especially since the markets can sometimes overreact to a bad quarter.
Diabetes specialist (NASDAQ: DXCM) saw its stock fall by over 40% just with the release of its latest earnings numbers. The sell-off might have you believe that the business is broken, or at least that it's in deep trouble. But is that really the case?
Let's take a look at whether DexCom is a stock to avoid or it's a good time to add it to your portfolio.
Source Fool.com
Dexcom Inc. Aktie
62,25 €
-1,44 %
Klare Kaufempfehlung: Dexcom Inc. erhält nur Buy-Einschätzungen.
Eine Steigerung von über 50% ist für Dexcom Inc. möglich, angesichts eines Kursziels von 121 € gegenüber 62.25 €.
